甲癌患者131I治疗出院标准及时间研究进展

Progress in Discharge Criteria & Time for 131I treatment of Thyroid Cancer Patients

131I治疗是分化型甲状腺癌患者术后安全、有效、重要的辅助治疗方式,同时有可能产生辐射危害。为了减少其辐射危害,甲状腺癌患者行大剂量131I治疗后需住院隔离治疗,其体内放射性活度、周围当量剂量率的高低等因素决定了患者需住院隔离时间的长短。本文介绍甲状腺癌患者131I治疗后出院标准、体内活度估算、辐射剂量的监测、住院隔离时间以及其预测因素等研究进展,为临床工作中实施规范、合理的出院标准以及进一步开展相关研究提供参考。

131 I treatment is a safe,effective and important adjuvant way for patients with differentiated thyroid cancer,and it may cause radiation damage. In order to reduce the radiation hazard,patients need to be hospitalized after treatment with large doses of131 I. The length of time that patients need to be hospitalized is determined by the in vivo radioactivity,the surrounding equivalent dose rate,and so on. The progress of discharge criteria,in vivo activity estimation,radiation dose monitoring,hospitalization isolation time and it’s predictive factors after131 I treatment in patients with thyroid cancer,is summarized. It’s expected to provides reference for the implementation of standardized and reasonable discharge standards in clinical work,and further research.